Scientific publications

November 2022
Intratumoral Sotigalimab with Pembrolizumab Activates Antigen Presenting cells and Induces Local and Distant Anti Tumor Responses in First line Metastatic Melanoma: Results of a Phase I/II Study
SITC Presentation
September 2022
A Multicenter Phase 2 Study of Sotigalimab (CD40 Agonist) in Combination with Neoadjuvant Chemoradiation for Resectable Esophageal and Gastroesophageal Junction (GEJ) Cancers
ESMO Poster
June 2022
Distinct Biosignatures Associate with Survival After Chemoimmunotherapy in a Randomized, Three-arm Phase II Study in Patients with Metastatic Pancreatic Cancer
ASCO Presentation
April 2022
Intratumoral CD40 Agonist Sotigalimab (APX005M) with Pembrolizumab Induces Broad Innate and Adaptive Immune Activation in Local and Distant Tumors in Metastatic Melanoma
AACR Presentation
March 2022
Elucidating Factors of Therapeutic Response to Immunotherapy Combined with Neoadjuvant Radiation Therapy for Rectal Cancer
Keystone Poster
November 2021
Innate: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer to Elucidate Local and Systemic Therapeutic Response
SITC Poster
November 2021
Phase II of CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
SITC Poster
November 2021
Multi-Omic Multi-Parameter Circulating Biomarker Analysis in Chemoimmunotherapy Combinations Identifies Unique Immune Activation Signatures in the Pancreatic Cancer Setting
SITC Poster
June 2021
Gemcitabine and nab-Paclitaxel ± Nivolumab ± CD40 Agonistic Monoclonal Antibody Sotigalimab (APX005M) in Participants with Untreated Metastatic Pancreatic Adenocarcinoma: Phase 2 Final Results
ASCO Poster
December 2020
First in Pediatrics Phase 1 Study Of CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors
ISPNO Presentation